KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma
Clinical trial NCT04469725 · TERMINATED
Trial details
- NCT number
- NCT04469725
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-02
- Primary completion
- 2023-07-07
- Enrollment
- 95
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.